Gabelli Multimedia Trust activity and dividend update within the NYSE Composite highlights portfolio focus, trading patterns, and institutional participation across multimedia sectors amid evolving ...

A new screening tool can identify the hidden driver of a silent killer through standard blood work, bypassing the need to ask ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years- Company is eligible to receive a $40 million milestone payment upon first ...

Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...

Gabelli's John Belton joins 'Closing Bell Overtime' to talk what he is expecting out of Nvidia quarterly results.

A growing share of U.S. families is reconsidering tightly packed calendars as children express a strong preference for time ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsIan Estepan - President ...